Remidio’s Medios AI shows significant promise in last-mile screening for referable glaucoma \
5 min read
\
\

Remidio’s Medios AI shows significant promise in last-mile screening for referable glaucoma

08-Jul-2022
Bangalore (Karnataka) [India], July 8 (ANI/PRNewswire): Glaucoma, one of the world's leading causes of irreversible blindness, is expected to affect an estimated 120 million by 2040, globally. Treatment options for the management of Referable Glaucoma (a stage of the disease where immediate treatment can help manage the disease better) exist, but a simple test to screen for this has been elusive. Today, the only way to detect those with Referable Glaucoma is a series of complex investigations often requiring multiple devices handled by Glaucoma Specialists.
08-Jul-2022 Business
\